E-DRUG: The Medicines Patent posts independent feasibility studies on Hepatitis C & Tuberculosis
------------------------------------------------
The Medicines Patent Pool (MPP) posted two independent studies today as part of its ongoing consultation process on the possibility of expanding into other disease areas. The feasibility studies explore the case for potential entry into hepatitis C and tuberculosis.
MPP commissioned Dalberg and the Center for Disease Analysis for the study on hepatitis C, and Trinity Partners and Elizabeth Gardiner to conduct the analysis for tuberculosis. The consultants were tasked with providing their own strategic assessment of whether and to what extent MPP’s model could be adapted to increase access to new and re-purposed products and promote innovation in these areas. MPP welcomes feedback from all stakeholders.
Please send your comments on the reports or any other questions you might feel appropriate to: consultation@medicinespatentpool.org by July 31.
To read the feasibility studies click here:
Feasibility study – MPP intervention in Hep C by Dalberg and CDA : http://www.medicinespatentpool.org/wp-content/uploads/MPP-Intervention-in-Hep-C_Dalberg_CDA.pdf
Feasibility study – MPP intervention in Tuberculosis by Trinity Partners: http://www.medicinespatentpool.org/wp-content/uploads/MPP-Intervention-in-TB-Trinity-Partners-.pdf
Milena Marra | Communications Officer | Medicines Patent Pool
Advancing innovation, Access and Public Health
Website<http://www.medicinespatentpool.org/> | Newsletter<http://www.medicinespatentpool.org/news\-room/newsletter/> | Twitter<http://twitter.com/MedsPatentPool> | LinkedIn<http://www.linkedin.com/company/medicines-patent-pool>
email: mmarra@medicinespatentpool.org